Navigation Links
Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine
Date:4/27/2011

After the manufacturer of the Alzheimer's drug memantine submitted a supplementary analysis of study data, the German Institute for Quality and Efficiency in Health Care (IQWiG) sees proof of a benefit of the drug for cognitive function, as well as indications of a benefit for activities of daily living, at least for a treatment period of 6 months. This changes the conclusions of the first IQWiG benefit assessment of 2009. IQWiG had repeatedly called upon the manufacturer Merz to provide a renewed analysis of study data appropriate to the research question.

Additional effort may also be worthwhile for manufacturers

IQWiG's Director Jrgen Windeler comments on the new assessment result: "As in many other projects, in the assessment of memantine the Institute was also confronted with gaps in the evidence. If this is the case, then we make suggestions as to how these gaps can be closed. Sometimes additional new studies are required; sometimes it suffices if the manufacturer provides or supplements data already available, as was the case for memantine. In the end, the additional effort paid off."

In the first IQWiG assessment, data from two studies were missing

In Germany the drug memantine is marketed under the tradenames "Axura" and "Ebixa", and is approved for the treatment of moderate to severe Alzheimer's disease. In a first benefit assessment , prepared after commissioning by the Federal Joint Committee (G-BA) and published in September 2009, IQWiG found no proof that patients with Alzheimer's disease could benefit from memantine. However, among other things, relevant information on two studies was missing, which the manufacturer had not provided to IQWiG.

Additional analysis did not consider all of the relevant studies

At the beginning of 2010, Merz submitted the results of these two studies, as well as additional analyses of a larger number of studies, to the G-BA. IQWiG subsequently published a second assessment in the form of a working paper in August 2010. However, this did not change the conclusions of the first report. This was also due to the fact that IQWiG could not utilize the additional analyses as presented by Merz. For example, among other things, Merz had again failed to include all of the relevant studies. However, in its working paper IQWiG described how an appropriate analysis of the data could be performed.

Absence of deterioration may also mean an improvement

These additional analyses, in which the data were processed appropriately, were finally submitted by Merz to the G-BA in October 2010. These were "responder analyses". In this type of analysis, a count is made of how many patients experience a notable improvement in their health status after treatment, i.e. are "responders".

For this purpose it is specified how big this difference has to be in a patient in order to be classified as an improvement. Then, both in the placebo and in the memantine groups, all patients are counted who at least achieved this improvement. In the case of a progressive disease such as Alzheimer's, the absence of deterioration may also be regarded as an improvement.

Indications of a benefit for activities of daily living

As the analysis now submitted shows, the number of patients whose short- and long-term memory (cognitive function) notably deteriorated over a period of at most 6 months was lower in the memantine group. IQWiG classifies this result as proof of a benefit.

Such a difference in favour of memantine was also shown for activities of daily living (e.g. concerning personal hygiene); however, this was considerably smaller. In addition, in contrast to the outcome "cognitive function", the criteria according to which patients were classified as treatment responders have not proved themselves through year-long testing in studies. This leads to greater uncertainty in the interpretation of results. Consequently, overall IQWiG assumes an indication - not proof - of a benefit of treatment with memantine for this outcome.

Long-term studies are lacking

It remains unclear whether memantine improves quality of life, as for this outcome the studies available still allow no conclusions to be drawn. The results for cognitive function and activities of daily living now submitted only apply with time restrictions, as none of the studies lasted longer than 6 months. "We still have no long-term studies. However, particularly for Alzheimer's drugs this type of study is urgently required, as they are usually taken for several years," says Jrgen Windeler.


'/>"/>

Contact: IQWiG
info@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. 3.1 Million Hispanic Americans Struggle With Arthritis
2. Woman Struggles to Control Cholesterol
3. Children living with relatives struggle with physical, mental health issues
4. Processed, Fatty Foods May Dumb Down Your Kids: Study
5. Safe & Secure Online Pharmacy Viamedic.com; Reaches Milestone of 1.5 Million Orders Processed
6. Processed Meat May Harm the Heart
7. Salmonella Tennessee Identified in a Processed Food Ingredient
8. Bling My Sling LL Announces Website Launch - A fashionable arm sling manufacturer, announce the opening of their new website bling-my-sling.com
9. Linguistics professor examines manufacturers prescription drug websites
10. Leading Electronic Cigarette Manufacturer Vapure Announces U.S. Made E-Liquid
11. Small Supplement And Vitamin Manufacturers Must Meet FDA cGMP Requirements By The End Of The Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare ... Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from ... (Part D) need to make changes during this period order for their new policy ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management ... injury, patients must find the one that works for them. When an inventor from ... machine that worked and decided to share it with others. , He developed a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... in the ECG Cables And ECG Leadwires Market owing to ... devices. On the other hand, the Asia-Pacific ... rate during the forecast period. The market players ... plc ( Ireland ), Koninklijke Philips N.V. ( ... ( China ), held major share of the ...
(Date:12/2/2016)... 2016 Quantum Radiology,s Mobile Breast Center (QR ... directly to women at the workplace, thereby maximizing convenience ... Delta Air Lines and SunTrust Bank, and community health ... of wellness initiatives. "I think it,s a ... them to have a mammogram without taking a large ...
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
Breaking Medicine Technology: